Physician profile
Bruce M Cotugno
NPI 1972580983
$274,552.49
in general payments reported to CMS, 2019-2025
74 companies · $18K in 2025
The $18K reported for 2025 was more than what 92% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52K · 2020: $30K · 2021: $59K · 2022: $74K · 2023: $24K · 2024: $17K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $39K · Food and Beverage: $20K · Travel and Lodging: $593 · Education: $285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $38,786.82 |
| Food and Beverage | $20,045.34 |
| Travel and Lodging | $593.33 |
| Education | $285.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $64,892.27 | 2019-2025 | Tysabri, Vumerity, Skyclarys |
| Abbvie INC. | $44,480.90 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Genzyme Corporation | $38,198.15 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $22,907.91 | 2021 | |
| Emd Serono, INC. | $18,971.21 | 2019-2025 | Mavenclad, Mavenclad |
| Genentech USA, INC. | $18,663.91 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Allergan, INC. | $16,875.51 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $15,078.69 | 2022 | |
| Ucb, INC. | $2,588.62 | 2019-2025 | Briviact, Nayzilam, Fintepla |
| Teva Pharmaceuticals USA, INC. | $2,530.57 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Livanova USA, INC. | $2,518.19 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Novartis Pharmaceuticals Corporation | $2,345.17 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $2,203.78 | 2020-2025 | Zeposia |
| Genentech, INC. | $1,797.90 | 2020-2021 | |
| Sk Life Science, INC. | $1,708.12 | 2020-2025 | Xcopri |
Show all 74 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $1,581.04 | 2019-2025 | Nuplazid, Daybue |
| Jazz Pharmaceuticals INC. | $1,157.29 | 2019-2025 | Epidiolex |
| Mdd US Operations, LLC | $1,113.83 | 2019-2025 | Gocovri, Gocovri, Apokyn |
| Acorda Therapeutics, INC | $1,032.41 | 2019-2024 | Inbrija |
| Eisai INC. | $747.61 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $740.97 | 2021-2022 | |
| Celgene Corporation | $691.35 | 2020-2025 | Zeposia |
| Neurocrine Biosciences, INC. | $690.24 | 2019-2025 | Ingrezza, Ongentys |
| Avanir Pharmaceuticals, INC. | $643.85 | 2019-2022 | |
| Lundbeck LLC | $632.62 | 2019-2025 | Vyepti |
| Lilly USA, LLC | $629.01 | 2019-2025 | Kisunla, Emgality, Amyvid |
| Amgen INC. | $624.16 | 2019-2025 | Aimovig, Uplizna |
| Argenx US, INC. | $619.05 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Neurelis, INC. | $615.23 | 2020-2024 | Valtoco |
| Pfizer INC. | $574.42 | 2023-2025 | |
| Amneal Pharmaceuticals LLC | $540.28 | 2019-2025 | Rytary, Crexont |
| Alexion Pharmaceuticals, INC. | $533.20 | 2019-2025 | Ultomiris |
| Greenwich Biosciences, INC. | $483.94 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $477.16 | 2023-2025 | Rexulti, Nuedexta |
| Mallinckrodt Enterprises LLC | $365.94 | 2019 | |
| Tg Therapeutics, INC. | $357.77 | 2023-2025 | |
| Kyowa Kirin, INC. | $332.86 | 2020-2025 | Nourianz |
| Sunovion Pharmaceuticals INC. | $316.65 | 2019-2022 | |
| Tanabe Pharma America, INC. | $302.78 | 2022-2025 | Radicava |
| Boston Scientific Corporation | $261.80 | 2020-2025 | General - Dbs |
| Impel Pharmaceuticals INC. | $244.51 | 2022-2023 | Trudhesa |
| Alnylam Pharmaceuticals INC. | $210.14 | 2023-2024 | Amvuttra, Onpattro |
| Supernus Pharmaceuticals, INC. | $209.04 | 2019-2022 | |
| Adamas Pharmaceuticals, INC. | $165.13 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $151.83 | 2020-2022 | |
| Ge Healthcare | $133.81 | 2019-2024 | |
| Csl Behring | $127.86 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $124.47 | 2019 | |
| Sumitomo Pharma America, INC. | $109.67 | 2023-2024 | Aptiom |
| W. L. Gore & Associates, INC. | $96.68 | 2021 | |
| Arbor Pharmaceuticals, INC. | $95.66 | 2019-2022 | |
| Horizon Therapeutics Plc | $87.85 | 2023 | Uplizna |
| Collegium Pharmaceutical, INC. | $83.52 | 2024-2025 | Xtampza, Belbuca |
| Grt US Holding, INC. | $83.51 | 2021-2022 | |
| Grifols USA, LLC | $82.36 | 2019-2025 | Gamunex-C |
| Bausch Health US, LLC | $66.36 | 2019 | |
| Currax Pharmaceuticals LLC | $66.08 | 2020-2023 | Onzetra Xsail |
| Merz Pharmaceuticals, LLC | $64.24 | 2023-2025 | Xeomin, Inbrija, Ampyra |
| Vertical Pharmaceuticals, LLC | $55.19 | 2019 | |
| Vanda Pharmaceuticals INC. | $54.84 | 2025 | Ponvory |
| Banner Life Sciences, LLC | $53.94 | 2021 | |
| Abbott Laboratories | $51.54 | 2021-2024 | Infinity |
| Upsher-Smith Laboratories LLC | $47.18 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $36.89 | 2020 | |
| Merck Sharp & Dohme LLC | $34.56 | 2020-2023 | Belsomra |
| Neuropace, INC. | $32.76 | 2022 | |
| Revance Therapeutics, INC. | $30.25 | 2024 | Daxxify |
| Catalyst Pharmaceuticals, INC. | $25.40 | 2023 | Firdapse |
| Merz North America, INC. | $22.50 | 2019 | |
| Octapharma USA, INC. | $17.46 | 2023 | Panzyga |
| Impel Pharmaceuticals LLC | $16.90 | 2025 | Trudhesa |
| Astrazeneca Pharmaceuticals LP | $15.86 | 2025 | Fasenra |
| Alfasigma USA, INC. | $14.39 | 2021 | |
| Scilex Pharmaceuticals INC. | $13.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Cotugno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.